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Age Related Macular Degeneration (AMD)
78.3 Million 
in 2015 
(Cascella R et al, 2016)
AMD Classification
Wisconsin Age-related Maculopathy Grading System (WARMGS) 
The Royal College of Ophthalmology, 2013
AMD














Coleman HR et al, 2008; Chen M et al, 2015; Cascella R et al, 2014; Knickelbein JE et al, 2015
Pathogenesis of AMD
IL-6
Activation of endothelial 
cells, lead to increase in 
vascular permeability and 
leakage of fluid and protein
Up-regulation of VEGF 
secretion 
Kauppinen A et al, 2016; Naldini A et al, 2005; Tracey KJ et al, 1994; Yildirim Z et al, 2012 
Interleukin-6
Crystal structure of IL-6
Pro-Inflammatory cytokine
AMD - elevated in
- Serum (Yildirim Z et al, 2012)
- Aqueous & Vitreous (Sato K et al, 2018; Abcouwe SF et al, 2013)
Dry eye disease – elevated in
- Tears (Yoon et al, 2007)
IL-6 Quantification








Rationale of Study 
Significant higher level of IL-6 found in serum, aqueous and
vitreous in AMD patient
Significant correlation between IL-6 and VEGF which is the
angiogenic factor in neovascular AMD














To evaluate the level of IL-6 in tears and serum and 
its associated factors in AMD patients
Specific Objectives
1. To compare the level of IL-6 in tears between AMD and Control
2. To compare the level of IL-6 in tears between Early and Late AMD
3. To compare the level of IL-6 in serum between AMD and Control
4. To compare the level of IL-6 in serum between Early and Late AMD
5. To identify the associated factors (AMD status, duration of AMD,













Design Comparative Cross-Sectional Study
Population Newly diagnosed patients with AMD and Control
Location Ophthalmology Clinic, Hospital USM
Duration June 2018 to May 2021
Ethical Approval
Human Research Ethics Committee, USM 
[USM/JEPeM/ 18100488]
Funding




• AMD patients 
• Age: 45 - 70 years old
Exclusion Criteria
• Vitreoretinal pathology 
(DR,CRVO)
• Refractive error > -5.00DS
• Other macular pathology
• Ocular surgery within last 6 
months
• History of ocular surface 
disease
• History of cornea pathology
• Ocular/systemic inflammation
• Chronic systemic disease
Tears and Serum Collection
Blood taking EDTA Tube
IL-6 Measurement
Human IL-6 ELISA Kit Laboratory Analysis




















Age (years) 66.73 (5.43)* 66.20 (4.13)* 64.30 (5.65)* 2.37 (2) 0.097a
Ethnicity
Malay 40 45 23 1.23 (2) 0.540b
Chinese 16 11 7
Gender
Female 33 32 18 0.07 (2) 0.964b
Male 23 24 12
Duration of AMD
(Months)
40.45 (23.74)* 38.04 (28.78)* NA 0.23 (1) 0.630c
*Mean (SD); aANOVA test; bChi-square test; cIndependent t-test; 
Abbreviation : AMD: Age-Related Macular Degeneration; nAMD: neovascular Age-Related Macular 
Clinical Profile
*Mean (SD); aANOVA test; bChi-square test; cIndependent t-test; 









Yes 51 43 24 4.33 (2) 0.115b
No 5 13 6
Types of Comorbid
Diabetes Mellitus 30 26 17 0.99 (2) 0.609b
Hypertension 40 38 21 0.17 (2) 0.918b
Dyslipidaemia 23 22 11 0.16 (2) 0.923b
Smoking Status
Non-smoker 43 44 25 0.51 (2) 0.776b
Active Smoker 13 12 5
IL-6 in Tears & Serum: AMD vs Control
aIndependent t-test; bANCOVA test adjusted with covariates: Age, Gender, Presence of Comorbidities & Smoking Status,  p<0.05, 
significant; cAdjusted with Bonferroni Correction
Variable AMD Control Mean Different
(95% CI)
stat (df) p-value
Tears IL-6 level (pg/ml)








































IL-6 in Tears & Serum: Early vs Late nAMD
aIndependent t-test; bANCOVA test adjusted with covariates: Age, Gender, Presence of Comorbidities, Smoking Status & Duration of AMD,  
p<0.05, significant; cAdjusted with Bonferroni Correction
Variable Early AMD Late nAMD Mean Different
(95% CI)
stat (df) p-value
Tears IL-6 level (pg/ml)
Crude Mean (SD) 22.33 (9.62) 21.60 (12.21) 0.73 
(-3.39, 4.85)
3.13 (110) 0.726a






0.04 (1, 106) 0.844b
Serum IL-6 level (pg/ml)
Crude Mean (SD) 10.11 (5.41) 13.89 (6.08) -3.78 
(-5.94, -1.63)
0.72 (110) 0.001a







Associated Factors for Tears IL-6
aSimple Linear Regression test, p<0.25, significant, bMultiple Linear Regression test, p<0.05, significant
Variable
Simple Linear Regressiona
Crude β 95% CI t-stat p-value
Duration of AMD
(Months)
-0.05 -0.13, 0.03 -1.27 0.207
Serum IL-6 level 
(pg/ml)
0.24 -0.07, 0.55 1.51 0.133
Smoking Status 1.17 -3.31, 5.65 0.52 0.606
AMD Status 0.73 -4.85, 3.39 -0.35 0.726
Multiple Linear Regressionb
Adj. β 95% CI t-stat p-value
-0.05 -0.13, 0.03 -1.20 0.235
0.17 -0.19, 0.53 0.92 0.359
1.50 -3.46, 6.46 0.60 0.550












IL-6 in Tears  
The mean level of IL-6 in tears significantly higher in AMD group compare to
Control group
Indicating active role of IL-6 in pathogenesis of AMD
- Increased level of vascular permeability and angiogenesis by stimulating the expression
of VEGF (Tzafra C et al, 1996)
- Increase endothelial permeability through its induction of gap formation between
adjacent cells (Naoko M et al,1992)
IL-6 in Tears  
No significance difference in the mean level of IL-6 in tears between Early AMD
and Late nAMD
Study done by Ulhaq et al, (2020) found no significant difference of IL-6 in vitreous and aqueous
between dry and wet AMD
IL-6 in Serum 
The mean level of serum IL-6 was significantly higher in AMD group compare to
control group. Further analysis also showed significant higher level of serum IL-6
in late nAMD group
• Serum IL-6 increased in AMD patients and recognized as an important factor in prognosis of
AMD progression (Yildrim et al, 2012)
• Positive correlation between systemic levels of IL-6 with progression of AMD (Klein R et al, 2014;
Seddon JM et al, 2005)
Associated Factors for Tears IL-6
1. No significant association with duration of AMD
The duration of AMD in our study was standardized from the day of diagnosis. This may not
correlate with the onset of disease.
Associated Factors for Tears IL-6
2. No significant association with serum IL-6 level
• Mean level of IL-6 was much higher in tears.
• May explained by the site of production of these inflammatory mediators
• Within the eye, structures like RPE, iris, ciliary body and muller cells were able to secret IL-6
(Ahmed HM et al, 2014)
Associated Factors for Tears IL-6
3. No significant association with smoking
• Different biochemical pathways in pathogenesis of AMD (Velilla S et al, 2013)
• Pro-oxidant compounds, cause oxidative damage to the RPE, contributes to the development
and progression of AMD, and the alterations in the metabolic support of the RPE cause
apoptosis of the photoreceptors (Beatty S et al, 2000; Jiyang C et al, 2000)
Associated Factors for Tears IL-6
• Possibility of involvement of other factors that determine AMD progression
• Future controlled studies are needed to explore the association of IL-6 with other factors in
AMD
4. No significant association with AMD status
Limitations
• Single centre study
• Lack of racial data variation





• More patients with advance dry AMD with GA
• Comprehensive data collection method













There was significantly higher mean IL-6 in both tears and serum in AMD
compared to Control group
Therefore, tears sample can be used as non-invasive biomarker for AMD
screening
1. There was no significant association between IL-6 in tears with duration of
AMD, serum IL-6, smoking status and AMD status
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